China's Shanghai Fosun joins race to buy India injectables maker Gland

China flag
China flag

China's Shanghai Fosun Pharmaceuticals said it is in the race to buy unlisted Hyderabad-based injectables maker Gland Pharma, joining Baxter International and buyout firm Advent International, for a company valued at around $1.5 billion.

In a notice to the Hong Kong Stock Exchange, Shanghai Fosun said its interest so far was non-binding and was made known through a unit of the Fosun conglomerate, Fosun Industrial.

Gland is backed by leveraged buyout firm KKR & Co., which along with the firm's founders hold around 96% of the company, according to reported figures. For Shanghai Fosun, the purchase would open a pathway into the valuable sales and manufacturing of sterile injectable medicines now dominated by Pfizer ($PFE) following its recent Hospira purchase.

Also in the fray, Reuters reported in April, is Ahmedabad-based Torrent Pharmaceuticals, which hails from the manufacturing hub of Gujarat.

KKR's 2013 original investment was about $200 million, according to Reuters, the largest ever private equity amount in the India drug industry at the time and that valued the company around $600 million.

Injectables in India have drawn attention in the past few years as firms like Jordan-based Hikma faced manufacturing quality issues with U.S-based operations in the space, and Mylan ($MYL) snapped up Indian injectables maker Strides Arcolab for $1.75 billion, which closed in 2014 and is now called Strides Shasun.

- here's the release
- here's a story in Livemint

Suggested Articles

After two months of “residential surveillance,” Fangliang Zhang has been officially arrested for suspected smuggling.

Samsung Biologics makes Lilly's COVID antibody drug, just as it disbands an AstraZeneca joint venture. AZ's ex-China R&D head launches new firm.

After a slow clinical development program, the companies have decided there's no commercial value to bringing their Rituxan biosimilar to the market.